CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance

Simply Wall St.01-13

AdvertisementLeadership moves and fresh guidance at CorMedix CorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603633968?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-01-13 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603633968","market":"sg","top_or_hot":-1,"title":"CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementLeadership moves and fresh guidance at CorMedix CorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 19:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementLeadership moves and fresh guidance at CorMedix CorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026","article_id":"2603633968","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603633968","pubTimestamp":1768302962,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Leadership moves and fresh guidance at CorMedix\nCorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$320 million, alongside appointing Mike Seckler as EVP & Chief Commercial Officer.\nSee our latest analysis for CorMedix.\nThe leadership changes and fresh 2026 revenue guidance arrive after a sharp pullback in CorMedix’s share price. The 7 day share price return shows a decline of 36.50% and the year to date...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"CorMedix(CRMD)新领导层变动后的估值和2026年收入指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1.5},"content_text":"AdvertisementLeadership moves and fresh guidance at CorMedix CorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$320 million, alongside appointing Mike Seckler as EVP & Chief Commercial Officer. See our latest analysis for CorMedix. The leadership changes and fresh 2026 revenue guidance arrive after a sharp pullback in CorMedix’s share price. The 7 day share price return shows a decline of 36.50% and the year to date share price return shows a decline of 41.20%. However, the 3 year total shareholder return of 62.50% suggests longer term holders have still seen gains, so recent momentum looks to be fading. If this kind of healthcare update has your attention, it could be a good moment to look across healthcare stocks for other treatment focused names catching interest. With CorMedix trading at US$7.15 and some models suggesting the shares sit at a steep intrinsic discount, the key question is whether recent weakness has opened up value or whether the current price already reflects future growth. Most Popular Narrative: 62.4% Undervalued With CorMedix last closing at US$7.15 against a widely followed fair value of US$19.00, the narrative frames the current price as a steep discount and anchors that view in revenue expansion, margins and a specific discount rate of 6.956%.  The acquisition of Melinta Therapeutics immediately diversifies and stabilizes CorMedix's revenue base by adding $125–$135 million in expected 2025 revenue from multiple acute care and infectious disease products, which should support top-line growth and enhance earnings visibility. Integration of Melinta's established hospital commercial infrastructure with CorMedix's assets is expected to unlock $35–$45 million in annual operating expense synergies, improving gross and net margins through increased operational efficiency and economies of scale.  Read the complete narrative. Curious how that acquisition, projected margin lift and the 6.956% discount rate combine to reach US$19.00 per share? The revenue bridge, earnings assumptions and future P/E expectations all sit inside this narrative, and one set of numbers does most of the heavy lifting. Result: Fair Value of $19 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if Melinta integration costs eat into those projected synergies or if key trials and label expansions encounter regulatory setbacks. Find out about the key risks to this CorMedix narrative.  Build Your Own CorMedix Narrative If you want to weigh the assumptions yourself and test different scenarios, you can build a version that fits your view in just a few minutes, Do it your way. A great starting point for your CorMedix research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? If CorMedix has sharpened your focus, do not stop here. Broaden your watchlist and give yourself more options when the next opportunity shows up.  Spot potential value stories early by checking out these 881 undervalued stocks based on cash flows that might be pricing in more pessimism than their cash flows suggest. Ride the next wave of automation and data insights by scanning these 26 AI penny stocks that are building real businesses around artificial intelligence. Target income-focused opportunities by reviewing these 12 dividend stocks with yields > 3% that combine regular payouts with underlying business fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603633968","isCrawlerRequest":true}